Skip to main content
SpringerLink
Log in

On the Metabolism of Prostaglandin E1 in Patients Suffering from Arterial Occlusive Disease

  • Conference paper
Prostaglandin E1 in Atherosclerosis

Summary

During passage through the lungs, prostaglandin E1 (PGE1) is inactivated enzymatically via 15-keto-PGE1 to 13,14-dihydro-15-keto-PGE1. Since the subsequent metabolic degradation by β-oxidation and co-oxidation takes appreciably longer, the half-life of the circulating metabolite 13,14-dihydro-15-keto-PGE1 is distinctly longer than that of the active PGE1. In the presence of plasma proteins this metabolite is unstable, and it can therefore only be measured accurately after transformation into the stable bicyclic degradation product 11-deoxy-13,14-dihydro-15-keto-11,β16ξ-cyclo-PGE1. The normal plasma levels found are 20–60 pg/ml. Intra-arterial infusion of PGE1 (10 µg over a period of 30 min) leads to a significant rise in the venous and arterial levels of the PGE1 metabolite. Since PGE1 is not completely extracted during passage through the lungs, there is also a slight rise in the venous level of active PGE1. This shows that after infusion, PGE1 is rapidly inactivated by enzymatic degradation. Thus, results indicating that PGE1 infusion has a longer lasting therapeutic effect cannot be explained by a direct action of the short-lived PGE1 or 15-keto-13,14-dihydro-PGE1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bothwell W, Verburg M, Wynalda M, Daniels EG, Fitzpatrick FA (1982) A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. J Pharmacol Exp Ther 220: 229–235

    PubMed  CAS  Google Scholar 

  2. Diekmann JM, Jobke A, Peskar BA, Hertting G (1977) Angiotensin II-induced contractions of rabbit splenic capsular strips and release of prostaglandins. Use of radioimmunoassays for prostaglandin E1 and E2. Naunyn Schmiedebergs Arch Pharmacol 297: 177–183

    Article  PubMed  CAS  Google Scholar 

  3. Eklund AE, Eriksson G, Olsson AG (1982) A controlled study showing significant short term effect of prostaglandin E1 in healing of ischemic ulcers of the lower limb in man. Prostaglandins Leukotrienes Med 8: 265–271

    Article  CAS  Google Scholar 

  4. Fitzpatrick FA, Aguirre R, Pike JE, Lincoln FH (1980) The stability of 13,14-dihydro-15-keto-PGE2. Prostaglandins 19: 917–931

    Article  PubMed  CAS  Google Scholar 

  5. Golub M, Zia P, Matsuno M, Horton R (1975) Metabolism of prostaglandin A1 and E1 in man. J Clin Invest 56: 1404–1410

    Article  PubMed  CAS  Google Scholar 

  6. Granström E (1979) Sources of error in prostaglandin and thromboxane radioimmunoassay. In: Albertini A, Da Prada M, Peskar BA (eds) Radioimmunoassays of drugs and hormones in cardiovascular medicine. Elsevier/Amsterdam, pp 229–238

    Google Scholar 

  7. Granström E, Hamberg M, Hansson G, Kindahl H (1980) Chemical instability of 15-keto-13,14-dihydro-PGE2: the reason for low assay reliability. Prostaglandins 19: 933–956

    Article  PubMed  Google Scholar 

  8. Hamberg M, Samuelsson B (1971) On the metabolism of prostaglandin E1 and E2 in man. J Biol Chem 246: 6713–6721

    PubMed  CAS  Google Scholar 

  9. Hirai M, Nakayama R (1986) Haemodynamic effects of intraarterial and intravenous administration of prostaglandin E1 in patients with peripheral arterial disease. Br J Surg 73: 20–23

    Article  PubMed  CAS  Google Scholar 

  10. Hubbard WC, Watson JT (1976) Determination of 15-keto-13,14-dihydro-metabolites of PGE2 and PGF2α in plasma using high performance liquid chromatography and gas chromatography — mass spectrometry. Prostaglandins 12: 21–35

    Article  PubMed  CAS  Google Scholar 

  11. Kloeze J (1969) Relationship between chemical structure and platelet-aggregation activity of prostaglandins. Biochim Biophys Acta 187: 285–292

    PubMed  CAS  Google Scholar 

  12. Olsson AG, Carlson LA (1976) Clinical, haemodynamic, and metabolic effects of intraarterial infusions of prostaglandin E1 in patients with peripheral vascular disease. Adv Prostaglandin Thromboxane Res 1: 426–432

    Google Scholar 

  13. Peskar BA, Simmet Th, Peskar BM (1986) Radioimmunoassay of prostaglandins and other cyclooxygenase products of arachidonate metabolism. In: Patrono C, Peskar BA (eds) Radioimmunoassay in basic and clinical pharmacology, Springer, Berlin Heidelberg New York Tokyo (to be published)

    Google Scholar 

  14. Peskar BM, Günther B, Steffens Ch, Kröner EE, Peskar BA (1980) Antibodies against dehydration products of 15-keto-13,14-dihydro-prostaglandin E2. FEBS Lett 115: 123–126

    Article  PubMed  CAS  Google Scholar 

  15. Rosenkranz B, Fischer C, Boeynams JM, Frölich JC (1983) Metabolic disposition of prostaglandin E1 in man. Biochim Biophys Acta 750: 231–236

    PubMed  CAS  Google Scholar 

  16. Samuelsson B, Gréen K (1974) Endogenous levels of 15-keto-dihydro-prostaglandins in human plasma. Parameters for monitoring prostaglandin synthesis. Biochem Med 11: 298–303

    Article  PubMed  CAS  Google Scholar 

  17. Weeks JR, Chandra Sekhar N, Ducharme DW (1969) Relative activity of prostaglandins E1, A1, E2 and A2 on lipolysis, platelet aggregation, smooth muscle and the cardiovascular system. J Pharm Pharmacol 21: 103–108

    Article  PubMed  CAS  Google Scholar 

  18. Whittle BJR, Moncada S, Vane JR (1978) Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins 16: 373–388

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Th. Simmet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. A. Peskar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. R. D. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Atherosclerosis Research Group, University of Vienna, Schwarzspanierstraße 17, 1090, Wien, Austria

    Helmut Sinzinger

  2. Sanol Schwarz GmbH, Mittelstraße 11-13, 4019, Monheim, Federal Republic of Germany

    Waltraud Rogatti

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Simmet, T., Peskar, B.A., Wolf, H.R.D. (1986). On the Metabolism of Prostaglandin E1 in Patients Suffering from Arterial Occlusive Disease. In: Sinzinger, H., Rogatti, W. (eds) Prostaglandin E1 in Atherosclerosis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71679-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71679-9_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-17240-6

  • Online ISBN: 978-3-642-71679-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation